Tafasitamab combined with lenalidomide and rituximab demonstrated a median OS of 22.4 months vs 13.9 months with placebo in patients with follicular lymphoma.
Approval Alert | Tafasitamab Plus Lenalidomide/RItuximab in R/R Follicular Lymphoma
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
3
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
4
Real World Outcomes of CAR T-Cell Therapy in Multiple Myeloma Including Older and Comorbid Patients
5